

# Samrat Pharmachem Limited

## **Manufacturers & Exporters of Pharmaceutical Chemicals**

#### Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4, Opp. PCI, Ankleshwar – 393 002,

Gujarat, India

Tel: (02646) 220774 Fax: (02646) 251291

Web: www.samratpharmachem.com CIN: L24230GJ1992PLC017820

#### **Corporate Office**

701/702, Business Square, M. A. Road, Andheri (West), Mumbai – 400 058, India. Tel: (91-22) 26701050/1/2 Fax: (91-22) 26701053

E: contact@samratpharmachem.in

#### April 14, 2021

To,
Department of Corporate Services,
BSE Limited
25th Floor, P J Towers,
Dalal Street,
Mumbai - 400 001.

Dear Sir,

#### Sub: Reconciliation of Share Capital Audit f.t.q.e. 31/03/2021

Pursuance to Regulation 76 of the SEBI (Depositories & Participants) Regulation 2018, we are forwarding herewith a Certificate issued by Practicing Company Secretary after conducting Reconciliation of Share Capital Audit for the guarter ended March 31, 2021.

Thanking you,

Yours faithfully, For Samrat Pharmachem Limited

Nishant Kankaria Company Secretary & Compliance Officer

## A. A. MULLA & ASSOCIATES

**Company Secretaries** 

Room No.603, A Wing, 6th Floor, Dhamm Seva CHS, Deluxe Building, Opp. Kurla Station East, Mumbai – 400 024. M: 9892237418 Email: aqueelmulla@gmail.com

**April 14, 2021** 

The Board of Directors, M/s. Samrat Pharmachem Limited Plot No. A2/3445, GIDC, Phase 4, Ankleshwar – 393 002, Gujarat.

Dear Sir,

Pursuance to Regulation 76 of the SEBI (Depositories & Participants) Regulation 2018, we are enclosing herewith a Certificate issued by us after conducting Reconciliation of Share Capital Audit for the quarter ended 31st March, 2021, as required under the said circular.

Please find the same in order & forward a copy of the same to the respective stock exchanges.

MEM. No. 2973

Yours faithfully,

For A.A. Mulla & Associates

**Company Secretaries** 

Aqueel A. Mulla **Proprietor** 

UDIN: F002973C000086562

# **Reconciliation of Share Capital Audit Report**

(As per Regulation 76 of the SEBI (Depositories & Participants) Regulation 2018).

Sr. No	Particulars	Details			
1.	For Quarter Ended	31st March, 2021			
2.	ISIN	INE103E01016			
3.	Face Value	Rs. 10			
4.	Name of the Company	Samrat Pharmachem Limit	ted		
5.	Registered Office Address	Plot No. A2/3445,			
		GIDC, Phase 4,			
		Ankleshwar – 393 002,			
		Gujarat.			
6.	Correspondence Address	701/702, Business Square,			
		M. A. Road,			
		Andheri (West),			
		Mumbai – 400 058.			
7.	Tel No. & Fax No.	Tel : (022) 26701050			
-	F 1 4 11	Fax : (022) 26701053			
8.	Email Address Website	contact@samratpharmachem.in			
9.	Names of the stock exchanges where the	www.samratpharmachem.com			
9.	company's securities are listed.	Mumbai			
10.	Issued Capital	No. of shares	% of total issued capital		
10.	Issued Capital	30,89,700	100.00 %		
11.	Listed Capital (Exchange Wise)	30,02,700	100.00 /0		
11.	As per company records	30,89,700	100.00 %		
	It is same for all the exchanges	30,03,700	100.00 /0		
12.	Held in dematerialized form in CDSL	4,25,104 13.76 %			
13.	Held in dematerialized form in NSDL	23,00,286 74.45 %			
14.	Physical	3,64,310 11.79 %			
15.	Total No. of shares (12+13+14)	30,89,700	100.00 %		
16.	Reasons for difference if any, between (10&11), (10&15), (11&15)		Nil		

17. Certifying the details of changes in share capital during the quarter under consideration as per table below:

Particulars ***	No. of shares	Applied / Not applied for listing	Listed on stock exchanges (specify names)	Whether intimated to CDSL	Whether intimated to NSDL	In-prin. Appr. Pending for SE (Specify Names)
Nil	Nil	Nil	Nil	Nil	Nil	Nil

\*\*\* Rights, Bonus, Preferential Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital Reduction, Forfeiture, any other (to specify)

18.	Registrar of members is updated (Yes/No)	Yes
	If not, updated upto which date	Not Applicable



19. Reference of previous quarter with regards to excess de-materialised shares, if any.	
20. Has the Company resolved the matter mentioned in Point No. 19 above in the current quarter? If not, reason why?	

21. Mention the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay:

Total No. of demat requests	No. of requests	No. of shares	Reason for delay
Confirmed after 21 days	0	0	-
Pending for more than 21 days	0	0	-

22.	Name, Tel No., Fax No. &	Name	:	Mr. Nishant Anandkumar Kankaria
	Membership No. of the Compliance	Tel No.	:	(91-22) 26701050
	Officer of the Co.	Fax No.	:	-
		Membership No.	:	ACS-59905
		Email	:	contact@samratpharmachem.in

23.	Name, Address, Tel No. & Fax No.,	Name	:	A. A. Mulla & Associates
	Regn No. of the Certifying CA/CS			Company Secretaries
		Address	:	Room No.603, A Wing, 6th Floor,
				Dhamm Seva CHS, Deluxe Building,
				Opp Kurla Station East,
				Mumbai-400024
		Tel No.	:	(91) 9892237418
		Membership No.	:	2973
		Email	:	aqueelmulla@gmail.com

24.	Appointment of common agency for	Name	: Link Intime India Pvt Ltd
	share registry work	Address	: C-101, 247 Park,
			L. B. S. Marg, Vikhroli (West),
			Mumbai – 400 083, Maharashtra.
		Tel No.	: (022) 49186000
		Fax No.	: (022) 49186060
		Email	: rnt.helpdesk@linkintime.co.in
		Kind Attn	: Ms. Shweta Poojari

25. Any other detail that the CA/CS may like to provide (eg BIFR Company, de-listing from SE, etc)

Date: April 14, 2021 Place: Mumbai

For A. A. Mulla & Associates

**Company Secretaries** 

Aqueel A Mulla **Proprietor** C.P. No. 3237 CS No. 2973

UDIN: F002973C000086562